SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:gup.ub.gu.se/170512"
 

Search: onr:"swepub:oai:gup.ub.gu.se/170512" > High-throughput int...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004000naa a2200541 4500
001oai:gup.ub.gu.se/170512
003SwePub
008240528s2013 | |||||||||||000 ||eng|
0247 a https://gup.ub.gu.se/publication/1705122 URI
0247 a https://doi.org/10.1016/j.ygyno.2012.11.0372 DOI
040 a (SwePub)gu
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Garcia-Dios, Diego A4 aut
2451 0a High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.
264 1b Elsevier BV,c 2013
520 a OBJECTIVE: Endometrial cancer patients may benefit from systemic adjuvant chemotherapy, alone or in combination with targeted therapies. Prognostic and predictive markers are needed, however, to identify patients amenable for these therapies. METHODS: Primary endometrial tumors were genotyped for >100 hot spot mutations in genes potentially acting as prognostic or predictive markers. Mutations were correlated with tumor characteristics in a discovery cohort, replicated in independent cohorts and finally, confirmed in the overall population (n=1063). RESULTS: PIK3CA, PTEN and KRAS mutations were most frequently detected, respectively in 172 (16.2%), 164 (15.4%) and 161 (15.1%) tumors. Binary logistic regression revealed that PIK3CA mutations were more common in high-grade tumors (OR=2.03; P=0.001 for grade 2 and OR=1.89; P=0.012 for grade 3 compared to grade 1), whereas a positive TP53 status correlated with type II tumors (OR=11.92; P<0.001) and PTEN mutations with type I tumors (OR=19.58; P=0.003). Conversely, FBXW7 mutations correlated with positive lymph nodes (OR=3.38; P=0.045). When assessing the effects of individual hot spot mutations, the H1047R mutation in PIK3CA correlated with high tumor grade and reduced relapse-free survival (HR=2.18; P=0.028). CONCLUSIONS: Mutations in PIK3CA, TP53, PTEN and FBXW7 correlate with high tumor grade, endometrial cancer type and lymph node status, whereas PIK3CA H1047R mutations serve as prognostic markers for relapse-free survival in endometrial cancer patients.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Reproduktionsmedicin och gynekologi0 (SwePub)302202 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Obstetrics, Gynaecology and Reproductive Medicine0 (SwePub)302202 hsv//eng
653 a Endometrial cancer
653 a Clinical molecular genetics
653 a Molecular biomarkers
653 a Oncogenes
653 a Tumor suppressor genes
7001 a Lambrechts, Diether4 aut
7001 a Coenegrachts, Lieve4 aut
7001 a Vandenput, Ingrid4 aut
7001 a Capoen, An4 aut
7001 a Webb, Penelope M4 aut
7001 a Ferguson, Kaltin4 aut
7001 a Anecs,4 aut
7001 a Akslen, Lars A4 aut
7001 a Claes, Bart4 aut
7001 a Vergote, Ignace4 aut
7001 a Moerman, Philippe4 aut
7001 a Van Robays, Johan4 aut
7001 a Marcickiewicz, Januszu Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för obstetrik och gynekologi,Institute of Clinical Sciences, Department of Obstetrics and Gynecology4 aut0 (Swepub:gu)xmarcj
7001 a Salvesen, Helga B4 aut
7001 a Spurdle, Amanda B4 aut
7001 a Amant, Frédéric4 aut
7102 a Göteborgs universitetb Institutionen för kliniska vetenskaper, Avdelningen för obstetrik och gynekologi4 org
7730 t Gynecologic Oncologyd : Elsevier BVg 128:2, s. 327-334q 128:2<327-334x 0090-8258x 1095-6859
8564 8u https://gup.ub.gu.se/publication/170512
8564 8u https://doi.org/10.1016/j.ygyno.2012.11.037

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view